Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

NEU-22-02

The goal of this double-blind prospective randomized clinical trial is to determine if the effect of intravenous erythropoietin is superior to the effect of intravenous methylprednisolone in cases of toxic optic neuropathy 4 weeks after therapeutic intervention. The main question it aims to answer: • Is there a difference in the visual recovery of toxic optic neuropathies treated with intravenous methylprednisolone in comparison with those treated with intravenous erythropoietin?

2022-04-05

2024-04-05

2024-04-05

Recruiting

Early phase I

18

Inclusion Criteria: * Both genres. * Age between 18 and 75 years. * Clinical diagnosis of toxic optic neuropathy (afferent pupillary defect, acquired dyschromatopsia, visual loss and bilateral prechiasmatic field defect). * Exposure with a temporal relationship of less than two weeks to a known toxicant for the function of the optic nerve. * Up to 21 days from symptom onset. * Informed consent signature. Exclusion Criteria: * History of previous optic neuropathy. * History of additional ophthalmological or neurological pathology that has caused permanent visual loss. * History of previous treatment with intravenous methylprednisolone or some other experimental treatment since the onset of symptoms. * Poorly controlled diabetes mellitus. * Poorly controlled systemic arterial hypertension. * Hemoglobin \>16 mg/dL * Patients with a history of thromboembolic event. * Patients with a history of coronary heart disease, myocardial infarction or cerebral vascular event. * Pregnancy or lactation.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized groups (2)\n\n1. Standard treatment (Intravenous methylprednisolone)\n2. Intervention (Intravenous erythropoietin)', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': "Participants won't be aware to which group they were assigned. Investigator in charge of assessing outcomes and analyzing data won't be aware to which group participants were assigned.", 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 18, 'type': 'ESTIMATED'}}

2023-02-28